EA201270661A1 - УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA201270661A1
EA201270661A1 EA201270661A EA201270661A EA201270661A1 EA 201270661 A1 EA201270661 A1 EA 201270661A1 EA 201270661 A EA201270661 A EA 201270661A EA 201270661 A EA201270661 A EA 201270661A EA 201270661 A1 EA201270661 A1 EA 201270661A1
Authority
EA
Eurasian Patent Office
Prior art keywords
reinforcing
replacement
methods
application
cell connections
Prior art date
Application number
EA201270661A
Other languages
English (en)
Inventor
Джастин П. Аннес
Дуглас А. Мелтон
Ли Л. Рубин
Гордон Веир
Original Assignee
Президент Энд Феллоуз Оф Гарвард Колледж
Зе Бригхам Энд Вуменз Хоспитал, Инк.
Джослин Диабетес Сентер, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Президент Энд Феллоуз Оф Гарвард Колледж, Зе Бригхам Энд Вуменз Хоспитал, Инк., Джослин Диабетес Сентер, Инк. filed Critical Президент Энд Феллоуз Оф Гарвард Колледж
Publication of EA201270661A1 publication Critical patent/EA201270661A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0676—Pancreatic cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/507—Pancreatic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/40—Nucleotides, nucleosides, bases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/65—MicroRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)

Abstract

Настоящее изобретение относится к способу стимуляции или усиления размножения или роста β-клеток путем контакта β-клетки с ингибитором аденозинкиназы (ADK), ингибитором S-аденозилгомоцистеингидролазы (SAHH) или активатором АМР-активируемой протеинкиназы (АМРК).
EA201270661A 2009-12-18 2010-12-17 УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA201270661A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28800109P 2009-12-18 2009-12-18
PCT/US2010/061075 WO2011075665A2 (en) 2009-12-18 2010-12-17 Beta-cell replication promoting compounds and methods of their use

Publications (1)

Publication Number Publication Date
EA201270661A1 true EA201270661A1 (ru) 2013-06-28

Family

ID=44167939

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201270661A EA201270661A1 (ru) 2009-12-18 2010-12-17 УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (14)

Country Link
US (1) US20130023491A1 (ru)
EP (1) EP2513298A4 (ru)
JP (1) JP2013514781A (ru)
KR (1) KR20120113228A (ru)
CN (1) CN102803474A (ru)
AU (1) AU2010330823A1 (ru)
BR (1) BR112012014925A2 (ru)
CA (1) CA2784596A1 (ru)
EA (1) EA201270661A1 (ru)
IL (1) IL220401A0 (ru)
MX (1) MX2012007026A (ru)
SG (1) SG181703A1 (ru)
WO (1) WO2011075665A2 (ru)
ZA (1) ZA201204521B (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103193781B (zh) * 2013-04-01 2015-12-23 济南大学 一种sahn酶蛋白的特异性抑制化合物及其合成方法
JP2016057488A (ja) * 2014-09-10 2016-04-21 株式会社ジャパンディスプレイ 自発光型表示装置
EP3332809A4 (en) * 2015-08-06 2019-04-10 Nitto Denko Corporation COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND PHARMACEUTICAL VACCINE COMPOSITION
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
BR112018067789B1 (pt) 2016-03-10 2023-12-12 Janssen Pharmaceutica Nv Análogos de nucleosídeos substituídos, composição farmacêutica que os compreende e uso
MX2019003843A (es) 2016-10-03 2019-06-24 Janssen Pharmaceutica Nv Análogos novedosos de carbanucleósidos sustituidos de sistema anular monocíclico y bicíclico para su uso como inhibidores de prmt5.
BR112019017466A2 (pt) 2017-02-27 2020-03-31 Janssen Pharmaceutica Nv Uso de biomarcadores na identificação de pacientes com câncer que serão responsivos a tratamento com um inibidor de prmt5
WO2018160534A1 (en) 2017-02-28 2018-09-07 Joslin Diabetes Center Protection of beta cells from immune attack
CA3084581A1 (en) 2017-11-20 2019-05-23 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
MA51004A (fr) 2017-12-08 2020-10-14 Janssen Pharmaceutica Nv Nouveaux analogues spirobicycliques
JP2021510153A (ja) * 2018-01-05 2021-04-15 アイカーン スクール オブ メディシン アット マウント サイナイ 膵臓ベータ細胞の増殖を増加させる方法、治療方法、および組成物
AU2019240065A1 (en) 2018-03-20 2020-09-24 Icahn School Of Medicine At Mount Sinai Kinase inhibitor compounds and compositions and methods of use
US11471497B1 (en) 2019-03-13 2022-10-18 David Gordon Bermudes Copper chelation therapeutics
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
TW202112375A (zh) 2019-06-06 2021-04-01 比利時商健生藥品公司 使用ｐｒｍｔ５抑制劑治療癌症之方法
LV15670B (lv) * 2021-03-10 2023-11-20 Latvijas Organiskās Sintēzes Institūts Jauni adenozilmerkaptāna atvasinājumi kā vīrusu m-RNS kapinga metiltransferāžu inhibitori

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547942A (en) * 1994-01-04 1996-08-20 Rapaport; Eliezer Method of treatment of diabetes mellitus by administration of adenosine 5'-t
WO2000047721A2 (en) * 1999-02-10 2000-08-17 Ontogeny, Inc. Methods of inducing insulin positive progenitor cells
EP1194168B1 (en) * 1999-06-23 2010-03-31 University Of Vermont And State Agricultural College Methods and products for manipulating uncoupling protein expression
US20040170705A1 (en) * 2001-03-08 2004-09-02 Dusan Miljkovic Compositions and methods for non-insulin glucose uptake
CA2488611C (en) * 2002-06-07 2011-11-15 Kylix, B.V. Compounds for modulating the activity of exchange proteins directly activated by camp (epacs)
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
WO2007075956A2 (en) * 2005-12-21 2007-07-05 The Govt. Of The Usa As Represented By The Secretary Of The Department Of Health & Human Services Methods for producing and using pancreatic endocrine cells
US9321800B2 (en) * 2009-04-22 2016-04-26 Gilead Sciences, Inc. 7-deazapurine nucleosides for therapeutic uses

Also Published As

Publication number Publication date
WO2011075665A2 (en) 2011-06-23
KR20120113228A (ko) 2012-10-12
EP2513298A2 (en) 2012-10-24
MX2012007026A (es) 2013-03-18
US20130023491A1 (en) 2013-01-24
EP2513298A4 (en) 2013-03-27
CN102803474A (zh) 2012-11-28
ZA201204521B (en) 2013-09-25
JP2013514781A (ja) 2013-05-02
AU2010330823A1 (en) 2012-07-05
WO2011075665A3 (en) 2011-11-17
BR112012014925A2 (pt) 2017-03-01
SG181703A1 (en) 2012-07-30
CA2784596A1 (en) 2011-06-23
IL220401A0 (en) 2012-08-30

Similar Documents

Publication Publication Date Title
EA201270661A1 (ru) УСИЛИВАЮЩИЕ РАЗМНОЖЕНИЕ β-КЛЕТОК СОЕДИНЕНИЯ И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
ES2401192T8 (es) Deazapurinas útiles como inhibidores de janus cinasas
BR112014003693A2 (pt) amino quinazolinas como inibidores de quinase
BR112013010484A2 (pt) derivados de coelenterazina e métodos de utilizar os mesmos
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
DK2089361T3 (da) Inhibitorer af natriumglucose-cotransportør 2 og fremgangsmåder til deres anvendelse
CY1116377T1 (el) Αναστολεις της ανθρωπινης πρωτεϊνικης φωσφατασης της τυροσινης και μεθοδοι χρησης
EA201270553A1 (ru) Ингибиторы тирозинкиназы брутона
AR061246A1 (es) Anticuerpos anti- dill4 y metodos que los usan
SV2010003718A (es) Inhibidores de bace
ZA200808536B (en) Deazapurines useful as inhibitors of janus kinases
EA201201143A1 (ru) Производные пиразола в качестве ингибиторов jak
GT201200132A (es) Antagonistas il-17a
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
UY30297A1 (es) Inhibidores de la quinasa c-fms-i
DK2073811T3 (da) Kinaseinhibitorer anvendelige til behandling af myeloproliferative sygdomme og andre proliferative sygdomme
NO20091423L (no) Pyrimidinderivater og deres anvendelse som kinaseinhibitorer
EA201100306A1 (ru) Производные циклогексиламида и их применение в качестве антагонистов рецептора crf-1
NO20083491L (no) Metode for fremstilling av sulfonamid-substituerts alkoholer og mellomprodukter for slike
EA201070473A1 (ru) Способ увеличения адсорбции ингибитора в области ствола скважины
DK2089516T3 (da) Fremgangsmåder til at forbedre indføringen af DNA i bakterielle celler
EA201300867A1 (ru) ИНГИБИТОРЫ КИНАЗЫ mTOR В КАЧЕСТВЕ АНТИВИРУСНЫХ АГЕНТОВ
WO2012006243A3 (en) Methods and compositions for the specific inhibition of beta-catenin by double-stranded rna
UA110598C2 (uk) Спосіб одержання кристалічної модифікації фіпронілу
PH12013502194A1 (en) Antibodies to egfl7 and methods for their use